Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura

A. M. Moser, H. Shalev, J. Kapelushnik

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Acute idiopathic (immune) thrombocytopenic purpura (ITP) in the pediatric population is a disease in which autoimmune features are mainly self-limited, with a reported mortality of 0.1-0.5 %. Major treatment requires intravenous gammaglobulins (IV IgG) and corticosteroids. Recently a new globulin, anti-D, has been introduced. The authors have treated 25 children suffering from acute idiopathic thrombocytopenic purpura, with an IV anti-D dose of 75 μg/kg as the first treatment. Eligibility criteria included a platelet count < 15,000 and Rh+. Post-treatment response was 76% > 20,000 platelets at 6-10 h and 80% > 50,000 platelets at 48 h; three patients developed chronic idiopathic thrombocytopenic purpura. There were 5/25 patients who did not respond to the initial dose and received IV IgG and corticosteroids, 2/5 with a positive response (platelets > 20,000). Side effects consisted of chills (9/25), fever > 38°C (6/25), headache and vomiting (1/25), hemolysis (20/25) from 0.9-6.9 g%, and decrease in hemoglobin levels. One patient needed a blood transfusion after his Hbg decreased from 12.4 to 5.5 g%. The results indicate that anti-D is an effective treatment in acute ITP, but with side effects. Administration of steroids and antipyretics prior to anti-D treatment may prevent the side effects.

Original languageEnglish
Pages (from-to)407-411
Number of pages5
JournalPediatric Hematology and Oncology
Issue number6
StatePublished - 1 Sep 2002
Externally publishedYes


  • Acute anti-D
  • Idiopathic thrombocytopenia


Dive into the research topics of 'Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this